Brief discussion of "subject to contract" clauses as reviewed in Singapore and English High Court cases.
Review of social media considerations for in-house counsel, including social media issues in recruitment and during employment.
A brief overview of anti-bribery and corruption laws in Europe, Brazil, Russia, India, and China.
This Wisdom of the Crowd addresses issues of conducting due diligence background investigations under the Foreign Corrupt Practices Act (FCPA) and similar international legislation.
Indemnities feature in many commercial contracts, but there are a number of common misconceptions about their nature, which can lead to surprising outcomes if claims under them are made or challenged. This article answers frequently asked questions, clears up some misunderstandings, and considers how the English courts have interpreted indemnities over the years. It also includes some drafting tips to help ensure the indemnity in your contract provides the protection you expect.
A reference guide for Private Equity and Venture Capital professional, adviser and lawyers. It sets out the current status of jurisdictions, implementation of new regulation and key considerations to take into account when deciding to invest in different European jurisdictions.
An easy reference guide to employee non-compete agreements across borders. It sets out the key considerations to take into account when drafting, updating and enforcing non-compete agreements and restrictive covenants in different jurisdictions in Europe, Africa, and the Middle East.
In Ust-Kamenogorsk Hydropower Plant JSC -v- AES Ust-Kamenogorsk Hydropower Plant LLP the UK Supreme Court confirmed that the English courts have the power to restrain non-European proceedings brought in violation of an arbitration agreement, even where no arbitration has been commenced or is contemplated. The decision is another example of the English courts' support of the arbitration process.
In a robust decision handed down by the English Court of Appeal, Novartis has been awarded an interim injunction against Hospira to prevent sales of generic zoledronic acid in the UK despite Novartis’ patents having been declared invalid by the English High Court. The Court of Appeal judgment represents a significant victory for Novartis and other innovators. This article discusses how this decision impacts innovators and generic companies alike, as well as the practical steps that parties should consider prior to the launch of a generic product.
A brief review of a chairman's obligations under UK law in poll and proxy voting scenarios.